News & Updates

Trastuzumab emtansine prolongs survival in metastatic breast cancer

10 Apr 2021

Treatment with trastuzumab emtansine extends progression-free and overall survival with no serious safety concerns in patients with metastatic HER-2 positive breast cancer, reports a study. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), thrombocytopaenia, and cancer antigen 15-3 are all associated with survival.

Trastuzumab emtansine prolongs survival in metastatic breast cancer

10 Apr 2021

Pharmacist intervention rectifies errors in parenteral nutrition prescriptions in cancer patients

09 Apr 2021

Pharmacists play a significant role in identifying and correcting total parenteral nutrition dosing errors for both micro- and macronutrients at a specialized cancer care hospital, which leads to improvements in total parenteral nutrition-related complications and switches to enteral feeding, results of a study have shown.

Pharmacist intervention rectifies errors in parenteral nutrition prescriptions in cancer patients

09 Apr 2021

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021 by

A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021

5-alpha-reductase inhibitors beneficial to men with prostate cancer

09 Apr 2021

Men with prostate cancer on active surveillance appear to fare well with 5-alpha-reductase inhibitors, which can help reduce both grade and volume progression without increasing the risk of developing high-grade tumours, a study has found.

5-alpha-reductase inhibitors beneficial to men with prostate cancer

09 Apr 2021

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

09 Apr 2021 by

Adding gemcitabine to pazopanib led to a significantly higher progression-free survival (PFS) rate in patients with advanced soft tissue sarcoma compared with pazopanib alone, according to the PAPAGEMO* trial.

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

09 Apr 2021

Early-phase trial evidence for RRMM treatment highly heterogenous

08 Apr 2021

While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.

Early-phase trial evidence for RRMM treatment highly heterogenous

08 Apr 2021

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

08 Apr 2021

Among women carrying BRCA1/2 mutation, the use of fertility treatment does not contribute to a discernible increase in breast cancer risk, according to a study.

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

08 Apr 2021

Long-term givinostat safe, effective in polycythaemia vera

07 Apr 2021

Givinostat, a histone-deacetylase inhibitor, is safe and effective for long-term use in patients with polycythaemia vera (PV), a recent study has found.

Long-term givinostat safe, effective in polycythaemia vera

07 Apr 2021

KRAS G12C inhibitors show promise in KRAS G12C-mutated NSCLC

07 Apr 2021 by

Two KRAS^G12C inhibitors have demonstrated promising efficacy in patients with advanced or metastatic KRAS^G12C-mutated non-small-cell lung cancer (NSCLC), a population with an unmet medical need for whom no targeted therapy was available until recently.

KRAS G12C inhibitors show promise in KRAS G12C-mutated NSCLC

07 Apr 2021

Narrow resection margins not linked to mortality, recurrence in Merkel cell carcinoma

06 Apr 2021

Excision with narrow margins does not predict mortality or recurrence in patients with Merkel cell carcinoma, results of a study have shown. Residual tumour, found primarily on deep surgical margins, is independently associated with prognosis.

Narrow resection margins not linked to mortality, recurrence in Merkel cell carcinoma

06 Apr 2021

News & Updates

Filter by Specialty:

Specialty:

Trastuzumab emtansine prolongs survival in metastatic breast cancer

Trastuzumab emtansine prolongs survival in metastatic breast cancer

Pharmacist intervention rectifies errors in parenteral nutrition prescriptions in cancer patients

Pharmacist intervention rectifies errors in parenteral nutrition prescriptions in cancer patients

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

5-alpha-reductase inhibitors beneficial to men with prostate cancer

5-alpha-reductase inhibitors beneficial to men with prostate cancer

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

Early-phase trial evidence for RRMM treatment highly heterogenous

Early-phase trial evidence for RRMM treatment highly heterogenous

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

Long-term givinostat safe, effective in polycythaemia vera

Long-term givinostat safe, effective in polycythaemia vera

KRAS G12C inhibitors show promise in KRAS G12C-mutated NSCLC

KRAS G12C inhibitors show promise in KRAS G12C-mutated NSCLC

Narrow resection margins not linked to mortality, recurrence in Merkel cell carcinoma

Narrow resection margins not linked to mortality, recurrence in Merkel cell carcinoma